Form 4: Achieve Life Sciences Director Kristen Slaoui Granted 31,500 Stock Options

Achieve Life Sciences, Inc. Director Kristen B. Slaoui was granted 31,500 stock options with an exercise price of $3.83, vesting fully by June 2026.

Summary

• Kristen B. Slaoui, a Director of Achieve Life Sciences, Inc. (ACHV), was granted 31,500 stock options.
• The options have an exercise price of $3.83 per share.
• The transaction date for the grant was June 6, 2025.
• These options will vest 100% on the earlier of June 6, 2026, or the date immediately prior to the Issuer's 2026 annual meeting of stockholders.
• The options have an expiration date of June 6, 2035.
• Following this transaction, Kristen B. Slaoui beneficially owns 31,500 stock options directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive signal, indicating continued commitment and aligning interests with shareholders. It's a standard compensation practice and not indicative of immediate negative news.

Positives

• The grant of stock options to a director aligns the director's interests with those of shareholders, as the options gain value if the stock price increases above the exercise price.
• The exercise price of $3.83 indicates the company's valuation at the time of the grant.

Future Outlook

The vesting schedule for the granted options indicates a future commitment and alignment of the director's incentives with the company's long-term performance, with full vesting expected by June 2026.

Industry Context

This Form 4 filing reflects a standard practice of granting equity compensation to directors, a common method across industries to incentivize long-term commitment and align leadership interests with shareholder value creation. The specific exercise price of $3.83 provides a snapshot of the company's valuation at the time of the grant within the biotechnology or pharmaceutical sector, where Achieve Life Sciences operates.

Stakeholder Impact

• Shareholders: The grant of options to a director aligns the director's financial interests with the long-term performance of the company, potentially benefiting shareholders if the stock price appreciates.
• Management/Directors: Kristen B. Slaoui receives additional equity compensation, incentivizing her continued contribution to the company's success.

Next Steps

• The stock options will vest 100% on the earlier of June 6, 2026, or the date immediately prior to the Issuer's 2026 annual meeting of stockholders.
• The director may choose to exercise these options at any time after vesting and before the expiration date of June 6, 2035, assuming the stock price is above the exercise price of $3.83.

Key Dates

Keywords

Achieve Life Sciences, ACHV, Form 4, SEC Filing, Insider Transaction, Stock Options, Director Compensation, Equity Grant, Kristen B. Slaoui